SEARCH

SEARCH BY CITATION

References

  • Akan, H., Antia, V.P., Kouba, M., Sinkó, J., Tănase, A.D., Vrhovac, R. & Herbrecht, R. (2013) Preventing invasive fungal disease in patients with haematological malignancies and the recipients of haematopoietic stem cell transplantation: practical aspects. Journal of Antimicrobial Chemotherapy, 68(Suppl. 3), iii5iii16.
  • Alastruey-Izquierdo, A., Cuenca-Estrella, M., Monzon, A., Mellado, E. & Rodriguez-Tudela, J.L. (2008) Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. Journal of Antimicrobial Chemotherapy, 61, 805809.
  • Alastruey-Izquierdo, A., Mellado, E., Peláez, T., Pemán, J., Zapico, S., Alvarez, M., Rodríguez-Tudela, J.L. & Cuenca-Estrella, M.; FILPOP Study Group (2013) Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrobial Agents and Chemotherapy, 57, 33803387.
  • Alcazar-Fuoli, L., Rodríguez-Tudela, J.L. & Mellado, E. (2008) Antifungal drug resistance in molds: clinical and microbiological factors. Current Fungal Infection Reports, 2, 3642.
  • Alcazar-Fuoli, L., Cuesta, I., Rodriguez-Tudela, J.L., Cuenca-Estrella, M., Sanglard, D. & Mellado, E. (2011) Three-dimensional models of 14 α-sterol demethylase (Cyp51A) from Aspergillus lentulus and Aspergillus fumigatus: an insight into differences in voriconazole interaction. International Journal of Antimicrobial Agents, 38, 426434.
  • Alexander, B.D., Johnson, M.D., Pfeiffer, C.D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S.A., Perlin, D.S. & Pfaller, M.A. (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clinical Infectious Diseases, 56, 17241732.
  • Arendrup, M.C. (2013) Candida and candidaemia. Danish Medical Journal, 60, B4698.
  • Arendrup, M.C., Fuursted, K., Gahrn-Hansen, B., Møller Jensen, I.M., Knudsen, J.D., Lundgren, B., Schønheyder, H.C. & Tvede, M. (2005) Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. Journal of Clinical Microbiology, 43, 44344440.
  • Arendrup, M.C., Garcia-Effron, G., Buzina, W., Mortensen, K.L., Reiter, N., Lundin, C., Jensen, H.E., Lass-Florl, C., Perlin, D.S. & Bruun, B. (2009) Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrobial Agents and Chemotherapy, 53, 11851193.
  • Arendrup, M.C., Cuenca-Estrella, M., Lass-Flörl, C. & Hope, W.; EUCAST-AFST (2012a) EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clinical Microbiology and Infection, 18, E246E247.
  • Arendrup, M.C., Cuenca-Estrella, M., Lass-Flörl, C. & Hope, W.W.; European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) (2012b) EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clinical Microbiology and Infection, 18, E248E250.
  • Azzola, A., Passweg, J.R., Habicht, J.M., Bubendorf, L., Tamm, M., Gratwohl, A. & Eich, G. (2004) Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection. Journal of Clinical Microbiology, 42, 48054808.
  • Bader, O., Weig, M., Reichard, U., Lugert, R., Kuhns, M., Christner, M., Held, J., Peter, S., Schumacher, U., Buchheidt, D., Tintelnot, K. & Groß, U.; MykoLabNet-D Partners (2013) cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrobial Agents and Chemotherapy, 57, 35133517.
  • Balajee, S.A., Lindsley, M.D., Iqbal, N., Ito, J., Pappas, P.G. & Brandt, M.E. (2007) Non-sporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods. Journal of Clinical Microbiology, 45, 27012703.
  • Balashov, S.V., Park, S. & Perlin, D.S. (2006) Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrobial Agents and Chemotherapy, 50, 20582063.
  • Barchiesi, F., Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E. & Scalise, G. (2006) Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrobial Agents and Chemotherapy, 50, 27192727.
  • Beyda, N.D., Lewis, R.E. & Garey, K.W. (2012) Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Annals of Pharmacotherapy, 46, 10861096.
  • Bhatt, V.R., Viola, G.M. & Ferrajoli, A. (2011) Invasive fungal infections in acute leukemia. Therapeutic Advances in Hematology, 2, 231247.
  • Blum, G., Perkhofer, S., Haas, H., Schrettl, M., Würzner, R., Dierich, M.P. & Lass-Flörl, C. (2008) Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrobial Agents and Chemotherapy, 52, 15531555.
  • Bow, E.J. (2008) Considerations in the approach to invasive fungal infection in patients with haematological malignancies. British Journal of Haematology, 140, 133152.
  • Bowyer, P., Moore, C.B., Rautemaa, R., Denning, D.W. & Richardson, M.D. (2011) Azole antifungal resistance today: focus on Aspergillus. Current Infectious Disease Reports, 13, 485491.
  • Bueid, A., Howard, S.J., Moore, C.B., Richardson, M.D., Harrison, E., Bowyer, P. & Denning, D.W. (2010) Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. Journal of Antimicrobial Chemotherapy, 65, 21162118.
  • Burgel, P.R., Baixench, M.T., Amsellem, M., Audureau, E., Chapron, J., Kanaan, R., Honoré, I., Dupouy-Camet, J., Dusser, D., Klaassen, C.H., Meis, J.F., Hubert, D. & Paugam, A. (2012) High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrobial Agents and Chemotherapy, 56, 869874.
  • Chamilos, G., Luna, M., Lewis, R.E., Bodey, G.P., Chemaly, R., Tarrand, J.J., Safdar, A., Raad, I.I. & Kontoyiannis, D.P. (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica, 91, 986989.
  • Chandrasekar, P. (2011) Management of invasive fungal infections: a role for polyenes. Journal of Antimicrobial Chemotherapy, 66, 457465.
  • Chowdhary, A., Kathuria, S., Randhawa, H.S., Gaur, S.N., Klaassen, C.H. & Meis, J.F. (2012) Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. Journal of Antimicrobial Chemotherapy, 67, 362366.
  • Chowdhary, A., Sharma, C., Kathuria, S., Hagen, F. & Meis, J.F. (2014) Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. Journal of Antimicrobial Chemotherapy, 69, 555557.
  • Cleveland, A.A., Farley, M.M., Harrison, L.H., Stein, B., Hollick, R., Lockhart, S.R., Magill, S.S., Derado, G., Park, B.J. & Chiller, T.M. (2012) Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clinical Infectious Diseases, 55, 13521361.
  • Clinical and Laboratory Standards Institute (2008a) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Informational Supplement, 3rd edn. CLSI document M27-S3, Clinical and Laboratory Standards Institute, Wayne, PA.
  • Clinical and Laboratory Standards Institute (2008b) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd edn, CLSI document M38–A2. Clinical and Laboratory Standards Institute, Wayne, PA.
  • Cornillet, A., Camus, C., Nimubona, S., Gandemer, V., Tattevin, P., Belleguic, C., Chevrier, S., Meunier, C., Lebert, C., Aupee, M., Caulet-Maugendre, S., Faucheux, M., Lelong, B., Leray, E., Guiguen, C. & Gangneux, J.P. (2006) Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clinical Infectious Diseases, 43, 577584.
  • Dannaoui, E., Borel, E., Persat, F., Piens, M.A. & Picot, S. (2000) Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. Journal of Medical Microbiology, 49, 601606.
  • Debono, M. & Gordee, R.S. (1994) Antibiotics that inhibit fungal cell wall development. Annual Reviews of Microbiology, 48, 471497.
  • Denning, D.W. (2003) Echinocandin antifungal drugs. Lancet, 362, 11421151.
  • Denning, D., Radford, S.A. & Oakley, K.L. (1997) Correlation between in-vitro susceptibility testing to itraconazole and invivo outcome of Aspergillus fumigatus infection. Journal of Antimicrobial Chemotherapy, 40, 401414.
  • Desnos-Ollivier, M., Moquet, O., Chouaki, T., Guérin, A.M. & Dromer, F. (2011) Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. Journal of Clinical Microbiology, 49, 23042306.
  • Diaz-Guerra, T.M., Mellado, E., Cuenca-Estrella, M. & Rodriguez-Tudela, J.L. (2003) A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 47, 11201124.
  • Dunkel, N., Liu, T.T., Barker, K.S., Homayouni, R., Morschhäuser, J. & Rogers, P.D. (2008) A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryotic Cell, 7, 11801190.
  • Eddouzi, J., Parker, J.E., Vale-Silva, L.A., Coste, A., Ischer, F., Kelly, S., Manai, M. & Sanglard, D. (2013) Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrobial Agents and Chemotherapy, 57, 31823193.
  • Ermishkin, L.N., Kasumov, K.M. & Potzeluyev, V.M. (1976) Single ionic channels induced in lipid bilayers by polyene antibiotics amphotericin B and nystatine. Nature, 262, 698699.
  • Eschenauer, G.A. & Carver, P.L. (2013) The evolving role of antifungal susceptibility testing. Pharmacotherapy, 33, 465475.
  • Eschertzhuber, S., Velik-Salchner, C., Hoermann, C., Hoefer, D. & Lass-Florl, C. (2008) Caspofungin-resistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transplant Infectious Disease, 10, 190192.
  • Espinel-Ingroff, A., Cuenca-Estrella, M., Fothergill, A., Fuller, J., Ghannoum, M., Johnson, E., Pelaez, T., Pfaller, M.A. & Turnidge, J. (2011a) Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrobial Agents and Chemotherapy, 55, 51505154.
  • Espinel-Ingroff, A., Fothergill, A., Fuller, J., Johnson, E., Pelaez, T. & Turnidge, J. (2011b) Wild-Type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrobial Agents and Chemotherapy, 55, 28552859.
  • Espinel-Ingroff, A., Cuenca-Estrella, M. & Cantón, E. (2013) EUCAST and CLSI: working together towards a harmonized method for antifungal susceptibility testing. Current Fungal Infection Reports, 7, 5967.
  • Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B. & Sanglard, D. (2011) Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One, 6, e17589.
  • Flowers, S.A., Barker, K.S., Berkow, E.L., Toner, G., Chadwick, S.G., Gygax, S.E., Morschhäuser, J. & Rogers, P.D. (2012) Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryotic Cell, 11, 12891299.
  • Forastiero, A., Mesa-Arango, A.C., Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Bernal-Martinez, L., Pelaez, T., Lopez, J.F., Grimalt, J.O., Gomez-Lopez, A., Cuesta, I., Zaragoza, O. & Mellado, E. (2013) Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrobial Agents and Chemotherapy, 57, 47694781.
  • Garcia-Effron, G., Katiyar, S.K., Park, S., Edlind, T.D. & Perlin, D.S. (2008) A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrobial Agents and Chemotherapy, 52, 23052312.
  • Garcia-Effron, G., Lee, S., Park, S., Cleary, J.D. & Perlin, D.S. (2009) Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-(beta)-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrobial Agents and Chemotherapy, 53, 36903699.
  • Gardiner, R.E., Souteropoulos, P., Park, S. & Perlin, D.S. (2005) Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Medical Mycology, 43(Suppl. 1), S299S305.
  • Guarro, J., Kantarcioglu, A.S., Horré, R., Rodriguez-Tudela, J.L., Estrella, M.C., Berenguer, J. & de Hoog, G.S. (2006) Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Medical Mycology, 44, 295327.
  • Hadrich, I., Makni, F., Neji, S., Cheikhrouhou, F., Bellaaj, H., Elloumi, M., Ayadi, A. & Ranque, S. (2012) Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection. Medical Mycology, 50, 829834.
  • Herbrecht, R., Maertens, J., Baila, L., Aoun, M., Heinz, W., Martino, R., Schwartz, S., Ullmann, A.J., Meert, L., Paesmans, M., Marchetti, O., Akan, H., Ameye, L., Shivaprakash, M. & Viscoli, C. (2010) Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplantation, 45, 12271233.
  • Howard, S.J., Webster, I., Moore, C.B., Gardiner, R.E., Park, S., Perlin, D.S. & Denning, D.W. (2006) Multi-azole resistance in Aspergillus fumigatus. International Journal of Antimicrobial Agents, 28, 450453.
  • Howard, S.J., Cerar, D., Anderson, M.J., Albarrag, A., Fisher, M.C., Pasqualotto, A.C., Laverdiere, M., Arendrup, M.C., Perlin, D.S. & Denning, D.W. (2009) Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerging Infectious Diseases, 15, 10681076.
  • Jensen, R.H., Johansen, H.K. & Arendrup, M.C. (2013) Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrobial Agents and Chemotherapy, 57, 614617.
  • Jiang, C., Dong, D., Yu, B., Cai, G., Wang, X., Ji, Y. & Peng, Y. (2013) Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. Journal of Antimicrobial Chemotherapy, 68, 778785.
  • Kanafani, Z.A. & Perfect, J.R. (2008) Resistance to antifungal agents: mechanisms and clinical impact. Clinical Infectious Diseases, 46, 120128.
  • Kelly, S.L., Lamb, D.C., Loeffler, J., Einsele, H. & Kelly, D.E. (1991) The G464S amino acid substitution in Candida albicans sterol 14α-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochemical and Biophysical Research Communications, 262, 174179.
  • Kelly, S.L., Lamb, D.C., Kelly, D.E., Manning, N.J., Loeffler, J., Hebart, H., Schumacher, U. & Einsele, H. (1997) Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Letters, 400, 8082.
  • Kelly, S.L., Lamb, D.C. & Kelly, D.E. (1999) Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiology Letters, 180, 171175.
  • Khan, Z., Ahmad, S., Joseph, L. & Chandy, R. (2012) Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen. PLoS One, 7, e32952.
  • Kontoyiannis, D.P., Marr, K.A., Park, B.J., Alexander, B.D., Anaissie, E.J., Walsh, T.J., Ito, J., Andes, D.R., Baddley, J.W., Brown, J.M., Brumble, L.M., Freifeld, A.G., Hadley, S., Herwaldt, L.A., Kauffman, C.A., Knapp, K., Lyon, G.M., Morrison, V.A., Papanicolaou, G., Patterson, T.F., Perl, T.M., Schuster, M.G., Walker, R., Wannemuehler, K.A., Wingard, J.R., Chiller, T.M. & Pappas, P.G. (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clinical Infectious Diseases, 50, 10911100.
  • Krogh-Madsen, M., Arendrup, M.C., Heslet, L. & Knudsen, J.D. (2006) Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clinical Infectious Diseases, 42, 938944.
  • Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J.D., Niimi, K., Holmes, A.R., Niimi, M. & Cannon, R.D. (2009) Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrobial Agents and Chemotherapy, 53, 354369.
  • Lanternier, F. & Lortholary, O. (2008) Liposomal amphotericin B: what is its role in 2008? Clinical Microbiology and Infection, 4, 7183.
  • Lass-Florl, C., Griff, K., Mayr, A., Petzer, A., Gastl, G., Bonatti, H., Freund, M., Kropshofer, G., Dierich, M.P. & Nachbaur, D. (2005) Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. British Journal of Haematology, 131, 201207.
  • Lewis, J.S., Wiederhold, N.P., Wickes, B.L., Patterson, T.F. & Jorgensen, J.H. (2013) Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrobial Agents and Chemotherapy, 57, 45594561.
  • van der Linden, J.W., Warris, A. & Verweij, P.E. (2011a) Aspergillus species intrinsically resistant to antifungal agents. Medical Mycology, 49(Suppl. 1), S82S89.
  • van der Linden, J.W., Snelders, E., Kampinga, G.A., Rijnders, B.J., Mattsson, E., Debets-Ossenkopp, Y.J., Kuijper, E.J., Van Tiel, F.H., Melchers, W.J. & Verweij, P.E. (2011b) Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerging Infectious Diseses, 17, 18461854.
  • van der Linden, J.W., Camps, S.M., Kampinga, G.A., Arends, J.P., Debets-Ossenkopp, Y.J., Haas, P.J., Rijnders, B.J., Kuijper, E.J., van Tiel, F.H., Varga, J., Karawajczyk, A., Zoll, J., Melchers, W.J. & Verweij, P.E. (2013) Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domestic homes. Clinical Infectious Diseases, 57, 513520.
  • Lockhart, S.R., Frade, J.P., Etienne, K.A., Pfaller, M.A., Diekema, D.J. & Balajee, S.A. (2011) Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrobial Agents and Chemotherapy, 55, 44654468.
  • Lockhart, S.R., Iqbal, N., Cleveland, A.A., Farley, M.M., Harrison, L.H., Bolden, C.B., Baughman, W., Stein, B., Hollick, R., Park, B.J. & Chiller, T. (2012) Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. Journal of Clinical Microbiology, 50, 34353442.
  • Lohberger, A., Coste, A.T. & Sanglard, D. (2014) Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence. Eukaryotic Cell, 13, 127142.
  • Madureira, A., Bergeron, A., Lacroix, C., Robin, M., Rocha, V., de Latour, R.P., Ferry, C., Devergie, A., Lapalu, J., Gluckmana, E., Socié, G., Ghannoum, M. & Ribaud, P. (2007) Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. International Journal of Antimicrobial Agents, 30, 551554.
  • Maertens, J., Marchetti, O., Herbrecht, R., Cornely, O.A., Flückiger, U., Frêre, P., Gachot, B., Heinz, W.J., Lass-Flörl, C., Ribaud, P., Thiebaut, A. & Cordonnier, C.; Third European Conference on Infections in Leukemia (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplantation, 46, 709718.
  • Malani, A.N. & Kauffman, C.A. (2007) Changing epidemiology of rare mould infections: implications for therapy. Drugs, 67, 18031812.
  • Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F.C., Odds, F.C. & Bossche, H.V. (1999) Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology, 145, 27012713.
  • Martel, C.M., Parker, J.E., Bader, O., Weig, M., Gross, U., Warrilow, A.G.S., Rolley, N., Kelly, D.E. & Kelly, S.L. (2010) Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrobial Agents and Chemotherapy, 54, 45274533.
  • Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M. & Rodriguez-Tudela, J.L. (2004) Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrobial Agents and Chemotherapy, 48, 27472750.
  • Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W.J., Verweij, P.E., Cuenca-Estrella, M. & Rodríguez-Tudela, J.L. (2007) A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrobial Agents and Chemotherapy, 51, 18971904.
  • Mellado, E., Alcazar-Fuoli, L., Cuenca-Estrella, M. & Rodriguez-Tudela, J.L. (2011) Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrobial Agents and Chemotherapy, 55, 54595468.
  • Moosa, M.Y., Alangaden, G.J., Manavathu, E. & Chandrasekar, P.H. (2002) Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis. Journal of Antimicrobial Chemotherapy, 49, 209213.
  • Moran, G.P., Sanglard, D., Donnelly, S.M., Shanley, D.B., Sullivan, D.J. & Coleman, D.C. (1998) Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrobial Agents and Chemotherapy, 42, 18191830.
  • Morio, F., Loge, C., Besse, B., Hennequin, C. & Le Pape, P. (2010) Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagnostic Microbiology and Infectious Disease, 66, 373384.
  • Morio, F., Pagniez, F., Lacroix, C., Miegeville, M. & Le Pape, P. (2012) Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. Journal of Antimicrobial Chemotherapy, 67, 21312138.
  • Mortensen, K.L., Mellado, E., Lass-Flörl, C., Rodriguez-Tudela, J.L., Johansen, H.K. & Arendrup, M.C. (2010) Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrobial Agents and Chemotherapy, 54, 45454549.
  • Nascimento, A.M., Goldman, G.H., Park, S., Marras, S.A., Delmas, G., Oza, U., Lolans, K., Dudley, M.N., Mann, P.A. & Perlin, D.S. (2003) Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrobial Agents and Chemotherapy, 47, 17191726.
  • Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K. & Marr, K. (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clinical Infectious Diseases, 48, 265273.
  • Oakley, K.L., Moore, C.B. & Denning, D.W. (1998) In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrobial Agents and Chemotherapy, 42, 27262730.
  • Pagano, L., Caira, M., Candoni, A., Offidani, M., Fianchi, L., Martino, B., Pastore, D., Picardi, M., Bonini, A., Chierichini, A., Fanci, R., Caramatti, C., Invernizzi, R., Mattei, D., Mitra, M.E., Melillo, L., Aversa, F., Van Lint, M.T., Falcucci, P., Valentini, C.G., Girmenia, C. & Nosari, A. (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica, 91, 10681075.
  • Pagano, L., Caira, M., Nosari, A., Van Lint, M.T., Candoni, A., Offidani, M., Aloisi, T., Irrera, G., Bonini, A., Picardi, M., Caramatti, C., Invernizzi, R., Mattei, D., Melillo, L., de Waere, C., Reddiconto, G., Fianchi, L., Valentini, C.G., Girmenia, C., Leone, G. & Aversa, F. (2007) Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study—Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clinical Infectious Diseases, 45, 11611170.
  • Pagano, L., Akova, M., Dimopoulos, G., Herbrecht, R., Drgona, L. & Blijlevens, N. (2011) Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 66(Suppl. 1), i5i14.
  • Pang, K.A., Godet, C., Fekkar, A., Scholler, J., Nivoix, Y., Letscher-Bru, V., Massias, L., Kauffmann-Lacroix, C., Elsendoorn, A., Uzunov, M., Datry, A. & Herbrecht, R. (2012) Breakthrough invasive mould infections in patients treated with caspofungin. Journal of Infection, 64, 424429.
  • Pappas, P.G., Alexander, B.D., Andes, D.R., Hadley, S., Kauffman, C.A., Freifeld, A., Anaissie, E.J., Brumble, L.M., Herwaldt, L., Ito, J., Kontoyiannis, D.P., Lyon, G.M., Marr, K.A., Morrison, V.A., Park, B.J., Patterson, T.F., Perl, T.M., Oster, R.A., Schuster, M.G., Walker, R., Walsh, T.J., Wannemuehler, K.A. & Chiller, T.M. (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clinical Infectious Diseases, 50, 11011111.
  • Park, S., Kelly, R., Kahn, J.N., Robles, J., Hsu, M.J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., Flattery, A., Gill, C., Chrebet, G., Parent, S.A., Kurtz, M., Teppler, H., Douglas, C.M. & Perlin, D.S. (2005) Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrobial Agents and Chemotherapy, 49, 32643273.
  • Park, B.J., Arthington-Skaggs, B.A., Hajjeh, R.A., Iqbal, N., Ciblak, M.A., Lee-Yang, W., Hairston, M.D., Phelan, M., Plikaytis, B.D., Sofair, A.N., Harrison, L.H., Fridkin, S.K. & Warnock, D.W. (2006) Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrobial Agents and Chemotherapy, 50, 12871292.
  • Park, H.G., Lee, I.S., Chun, I.J., Yun, C.H., Johnston, J.B., Ortiz de Montellon, P.R. & Kima, D. (2011) Heterologous expression and characterization of the sterol 14α-Demethylase CYP51F1 from Candida albicans. Archives of Biochemistry and Biophysics, 509, 915.
  • Paterson, P.J., Seaton, S., Prentice, H.G. & Kibbler, C.C. (2003) Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. Journal of Antimicrobial Chemotherapy, 52, 873876.
  • Pelaez, T., Gijón, P., Bunsow, E., Bouza, E., Sánchez-Yebra, W., Valerio, M., Gama, B., Cuenca-Estrella, M. & Mellado, E. (2012) Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis. Journal of Clinical Microbiology, 50, 25312534.
  • Perea, S., López-Ribot, J.L., Wickes, B.L., Kirkpatrick, W.R., Dib, O.P., Bachmann, S.P., Keller, S.M., Martinez, M. & Patterson, T.F. (2002) Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrobial Agents and Chemotherapy, 46, 16951703.
  • Perlin, D.S. (2007) Resistance to echinocandin-class antifungal drugs. Drug Resistance Updates, 10, 121130.
  • Perlin, D.S. (2011) Current perspectives on echinocandin class drugs. Future Microbiology, 6, 441457.
  • Pfaller, M.A. (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. American Journal of Medicine, 125, S3S13.
  • Pfaller, M.A. & Diekema, D.J. (2012) Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. Journal of Clinical Microbiology, 50, 28462856.
  • Pfaller, M.A., Diekema, D.J., Ghannoum, M.A., Rex, J.H., Alexander, B.D., Andes, D., Brown, S.D., Chaturvedi, V., Espinel-Ingroff, A., Fowler, C.L., Johnson, E.M., Knapp, C.C., Motyl, M.R., Ostrosky-Zeichner, L., Sheehan, D.J. & Walsh, T.J.; Clinical and Laboratory Standards Institute Antifungal Testing Subcommittee (2009) Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. Journal of Clinical Microbiology, 47, 31423146.
  • Pfaller, M.A., Diekema, D.J., Gibbs, D.L., Newell, V.A., Ellis, D., Tullio, V., Rodloff, A., Fu, W. & Ling, T.A.; the Global Antifungal Surveillance Group (2010) Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. Journal of Clinical Microbiology, 48, 13661377.
  • Pfaller, M.A., Diekema, D.J., Andes, D., Arendrup, M.C., Brown, S.D., Lockhart, S.R., Motyl, M. & Perlin, D.S.; CLSI Subcommittee for Antifungal Testing (2011) Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resistance Updates, 14, 164176.
  • Pfaller, M.A., Castanheira, M., Lockhart, S.R., Ahlquist, A.M., Messer, S.A. & Jones, R.N. (2012) Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. Journal of Clinical Microbiology, 50, 11991203.
  • Pinjon, E., Moran, G.P., Jackson, C.J., Kelly, S.L., Sanglard, D., Coleman, D.C. & Sullivan, D.J. (2003) Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrobial Agents and Chemotherapy, 47, 24242437.
  • Puig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J.M., Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M. & Almirante, B.; The CANDIPOP Project; GEIH-GEMICOMED (SEIMC); REIPI (2014) Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clinical Microbiology and Infection, 20, 245254.
  • Rath, P.M., Buchheidt, D., Spiess, B., Arfanis, E., Buer, J. & Steinmann, J. (2012) First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrobial Agents and Chemotherapy, 56, 60606061.
  • Rocha, E.M., Garcia-Effron, G., Park, S. & Perlin, D.S. (2007) A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy, 51, 41744176.
  • Rodriguez-Tudela, J.L., Alcazar-Fuoli, L., Mellado, E., Alastruey-Izquierdo, A., Monzon, A. & Cuenca-Estrella, M. (2008a) Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrobial Agents Chemotherapy, 52, 24682472.
  • Rodriguez-Tudela, J.L., Alcazar-Fuoli, L., Cuesta, I., Alastruey-Izquierdo, A., Monzon, A., Mellado, E. & Cuenca-Estrella, M. (2008b) Clinical relevance of resistance to antifungals. International Journal of Antimicrobial Agents, 32(Suppl. 2), S111S113.
  • Seyedmousavi, S., Hashemi, S.J., Zibafar, E., Zoll, J., Hedayati, M.T., Mouton, J.W., Melchers, W.J. & Verweij, P.E. (2013) Azole-resistant Aspergillus fumigatus, Iran. Emerging Infectious Diseases, 19, 832834.
  • Shoham, S. (2013) Emerging fungal infections in solid organ transplant recipients. Infectious Disease Clinics of North America, 27, 305316.
  • Silva, A.P., Miranda, I.M., Guida, A., Synnott, J., Rocha, R., Silva, R., Amorim, A., Pina-Vaz, C., Butler, G. & Rodrigues, A.G. (2011) Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrobial Agents and Chemotherapy, 55, 35463556.
  • Snelders, E., van der Lee, H.A., Kuijpers, J., Rijs, A.J., Varga, J. & Samson, R.A. (2008) Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Medicine, 5, e219.
  • Snelders, E., Huis In ‘t Veld, R.A., Rijs, A.J., Kema, G.H., Melchers, W.J. & Verweij, P.E. (2009) Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Applied Environmental Microbiology, 75, 40534057.
  • Staab, J.F., Kahn, J.N. & Marr, K.A. (2010) Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrobial Agents and Chemotherapy, 54, 49924998.
  • Steinbach, W.J., Benjamin, D.K. Jr, Kontoyiannis, D.P., Perfect, J.R., Lutsar, I., Marr, K.A., Lionakis, M.S., Torres, H.A., Jafri, H. & Walsh, T.J. (2004) Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clinical Infectious Diseases, 39, 192198.
  • Stevens, D.A., White, T.C., Perlin, D.S. & Selitrennikoff, C.P. (2005) Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagnostic Microbiology and Infectious Diseases, 51, 173178.
  • Taff, H.T., Mitchell, K.F., Edward, J.A. & Andes, D.R. (2013) Mechanisms of Candida biofilm drug resistance. Future Microbiology, 8, 13251337.
  • Tortorano, A.M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C.C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S. & Grillot, R.; ECMM Working Group on Candidaemia (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. European Journal of Clinical Microbiology & Infectious Diseases, 23, 317322.
  • Ullmann, A.J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M.C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., Cornely, O.A., Donnelly, JP, Garbino, J, Groll, A.H., Hope, W.W., Jensen, H.E., Kullberg, B.J., Lass-Flörl, C., Lortholary, O., Meersseman, W., Petrikkos, G., Richardson, M.D., Roilides, E., Verweij, P.E. & Cuenca-Estrella, M.; ESCMID Fungal Infection Study Group (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clinical Microbiology and Infection, 18(Suppl. 7), 5367.
  • Vandeputte, P., Larcher, G., Bergés, T., Renier, G., Chabasse, D. & Bouchara, J.P. (2005) Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrobial Agents Chemotherapy, 49, 46084615.
  • Vermeulen, E., Maertens, J., Schoemans, H. & Lagrou, K. (2012) Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Eurosurveillance, 17, pii:20326.
  • Verweij, P.E., Mellado, E. & Melchers, W.J. (2007) Multiple-triazole-resistant aspergillosis. New England Journal of Medicine, 356, 14811483.
  • Verweij, P.E., Howard, S.J., Melchers, W.J. & Denning, D.W. (2009a) Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resistance Updates, 12, 141147.
  • Verweij, P.E., Snelders, E., Kema, G.H., Mellado, E. & Melchers, W.J. (2009b) Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? The Lancet Infectious Diseases, 9, 789795.
  • Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, A., Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., Paesmans, M., Ameye, L., Shivaprakash, M., Ullmann, A.J. & Maertens, J.; Infectious Disease Group of the EORTC (2009) An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. Journal of Antimicrobial Chemotherapy, 64, 12741281.
  • Walker, L.A., Gow, N.A. & Munro, C.A. (2010) Fungal echinocandin resistance. Fungal Genetics and Biology, 47, 117126.
  • Walsh, T.J. & Gamaletsou, M.N. (2013) Treatment of fungal disease in the setting of neutropenia. Hematology, 2013, 423427.
  • Walsh, T.J., Anaissie, E.J., Denning, D.W., Herbrecht, R., Kontoyiannis, D.P., Marr, K.A., Morrison, V.A., Segal, B.H., Steinbach, W.J., Stevens, D.A., van Burik, J.-A., Wingard, J.R. & Patterson, T.F. (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 46, 327360.
  • Wisplinghoff, H., Ebbers, J., Geurtz, L., Stefanik, D., Major, Y., Edmond, M.B., Wenzel, R.P. & Seifert, H. (2014) Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. International Journal of Antimicrobial Agents, 43, 7881.